Evidence map›Paper›PMID 41476571›Full record

ReviewJournal of pathology informatics2026

Digital pathology imaging artificial intelligence in cancer research and clinical trials: An NCI workshop report.

Hala R Makhlouf, Miguel R Ossandon, Keyvan Farahani, Irina Lubensky, Lyndsay N Harris

Abstract readReview
In one paragraph

Review in Journal of pathology informatics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Hala R MakhloufDivision of Cancer Treatment and Diagnosis, Cancer Diagnosis Program, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Miguel R OssandonDivision of Cancer Treatment and Diagnosis, Cancer Diagnosis Program, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Keyvan FarahaniNational Heart Lung and Blood Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Irina LubenskyDivision of Cancer Treatment and Diagnosis, Cancer Diagnosis Program, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Lyndsay N HarrisDivision of Cancer Treatment and Diagnosis, Cancer Diagnosis Program, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Digital pathology imaging (DPI) is a rapidly advancing field with increasing relevance to cancer diagnosis, research, and clinical trials through large-scale image analysis and artificial intelligence (AI) integration. Despite these advances, regulatory adoption in digital pathology (DP) has lagged; to date, only three AI/ML Software as a Medical Device tool have received FDA clearance, highlighting a validation dataset gap rather than an absence of regulatory pathways. On March 6-7, 2024, the National Cancer Institute held a virtual workshop titled "Digital Pathology Imaging-Artificial Intelligence in Cancer Research and Clinical Trials," bringing together experts in pathology, radiology, oncology, data science, and regulatory fields to assess current challenges, practical solutions, and future directions. This report summarizes expert opinions on key issues related to the use of DPI in cancer research and clinical trials, including data standardization, de-identification, and the application of Digital Imaging and Communication in Medicine (DICOM) standards. Key topics included data standardization, image quality assurance, validation strategies, AI applications, integration in clinical trials, biobanking, intellectual property, investigators' needs, and lessons from digital cytology and radiology domains. Solutions discussed included adoption of open standards such as DICOM, centralized imaging portals, and scalable cloud-based platforms. The expert consensus outlined in this report is intended to guide the development of DPI infrastructure, standardization, support AI validation, and align regulatory and data-sharing practices to advance precision oncology.

Indexed as

Artificial intelligence (AI)BiobankingClinical trialsData sharingDe-identificationDICOM WSIDigital pathology imaging (DPI)PathomicsPrecision oncologyRegulatory complianceStandardizationValidation frameworksWhole-slide imaging (WSI)

Identifiers

PMID41476571
PMCPMC12753273

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.